Gene therapy for type 1 diabetes: a novel approach for targeted treatment of autoimmunity
AUTOR(ES)
Creusot, Rémi J.
FONTE
American Society for Clinical Investigation
RESUMO
It has been difficult to develop therapies that target those T cells initiating and mediating the pathogenesis of autoimmune disease. Indeed, most current treatments indiscriminately affect both the autoreactive T cells and the “good” T cells, putting the patient at risk of compromised immune function. A new approach raises the possibility of targeted therapy for autoimmunity. Transplantation of hematopoietic stem cells modified to express a protective form of MHC class II corrects a defect in central tolerance. This method contrasts with other targeted therapies that attempt to modify peripheral tolerance, which is also defective in type 1 diabetes mellitus.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=518674Documentos Relacionados
- Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse
- Antigen-Based Therapy for the Treatment of Type 1 Diabetes
- Hypoglycemia in type 1 diabetes: a burden to worry about during treatment
- Type 1 diabetes: recent developments
- Immunotherapy for the Prevention and Treatment of Type 1 Diabetes: Human trials and a look into the future